Hydromorphone intranasal - Impel Neuropharma

Drug Profile

Hydromorphone intranasal - Impel Neuropharma

Alternative Names: INP-101

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Impel NeuroPharma
  • Class Analgesics; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 03 Nov 2017 Chemical structure information added
  • 30 Oct 2017 Discontinued - Clinical-Phase-Unknown for Pain in USA (Intranasal) (Impel Neuropharma pipeline, October 2017)
  • 05 Oct 2015 Clinical trials in Pain in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top